163 related articles for article (PubMed ID: 29069891)
1. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease.
Gweon TG; Park JH; Kim BW; Choi YK; Kim JS; Park SM; Kim CW; Kim HG; Chung JW;
Gut Liver; 2018 Jan; 12(1):46-50. PubMed ID: 29069891
[TBL] [Abstract][Full Text] [Related]
2. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole.
Yoshida N; Kamada K; Tomatsuri N; Suzuki T; Takagi T; Ichikawa H; Yoshikawa T
Dig Dis Sci; 2010 Dec; 55(12):3393-8. PubMed ID: 20198424
[TBL] [Abstract][Full Text] [Related]
3. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease.
Adachi K; Furuta K; Miwa H; Oshima T; Miki M; Komazawa Y; Iwakiri K; Furuta T; Koike T; Shimatani T; Kinoshita Y
Dig Dis Sci; 2012 Jun; 57(6):1609-17. PubMed ID: 22367114
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.
Fujiwara S; Morita Y; Toyonaga T; Kawakami F; Itoh T; Yoshida M; Kutsumi H; Azuma T
J Gastroenterol; 2011 May; 46(5):595-602. PubMed ID: 21359522
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection--a randomized controlled study.
Kato T; Araki H; Onogi F; Ibuka T; Sugiyama A; Tomita E; Nagaki M; Moriwaki H
J Gastroenterol; 2010 Mar; 45(3):285-90. PubMed ID: 19957195
[TBL] [Abstract][Full Text] [Related]
6. Volume, distribution and acidity of gastric secretion on and off proton pump inhibitor treatment: a randomized double-blind controlled study in patients with gastro-esophageal reflux disease (GERD) and healthy subjects.
Steingoetter A; Sauter M; Curcic J; Liu D; Menne D; Fried M; Fox M; Schwizer W
BMC Gastroenterol; 2015 Sep; 15():111. PubMed ID: 26328588
[TBL] [Abstract][Full Text] [Related]
7. Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
Nakamura K; Ihara E; Akiho H; Akahoshi K; Harada N; Ochiai T; Nakamura N; Ogino H; Iwasa T; Aso A; Iboshi Y; Takayanagi R
Gut Liver; 2016 Nov; 10(6):917-924. PubMed ID: 27282261
[TBL] [Abstract][Full Text] [Related]
8. Contributing factors to gastric ulcer healing after endoscopic submucosal dissection including the promoting effect of rebamipide.
Kobayashi M; Takeuchi M; Hashimoto S; Mizuno K; Sato Y; Narisawa R; Aoyagi Y
Dig Dis Sci; 2012 Jan; 57(1):119-26. PubMed ID: 21842241
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy of Polaprezinc Plus Proton Pump Inhibitor and Rebamipide Plus Proton Pump Inhibitor Treatments for Endoscopic Submucosal Dissection-induced Ulcers.
Jung DH; Park JC; Lee YC; Lee SK; Shin SK; Chung H; Park JJ; Kim JH; Youn YH; Park H
J Clin Gastroenterol; 2021 Mar; 55(3):233-238. PubMed ID: 32341237
[TBL] [Abstract][Full Text] [Related]
10. Impact of pantoprazole on duodeno-gastro-esophageal reflux (DGER).
Kunsch S; Neesse A; Linhart T; Steinkamp M; Fensterer H; Adler G; Gress TM; Ellenrieder V
Z Gastroenterol; 2009 Mar; 47(3):277-82. PubMed ID: 19280541
[TBL] [Abstract][Full Text] [Related]
11. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent.
Sun WH; Tsuji S; Tsujii M; Gunawan ES; Kawai N; Kimura A; Kakiuchi Y; Yasumaru M; Iijima H; Okuda Y; Sasaki Y; Hori M; Kawano S
J Pharmacol Exp Ther; 2000 Nov; 295(2):447-52. PubMed ID: 11046075
[TBL] [Abstract][Full Text] [Related]
12. Effect of Acid Suppression on Peripheral T-Lymphocyte Subsets and Immunohistochemical Esophageal Mucosal Changes in Patients With Gastroesophageal Reflux Disease.
Ahmed Osman H; Aly SS; Mahmoud HS; Ahmed EH; Salah Eldin EM; Abdelrahim EA; El Masry MA; Herdan RA; Hassan MH
J Clin Gastroenterol; 2019 Oct; 53(9):e362-e370. PubMed ID: 30119091
[TBL] [Abstract][Full Text] [Related]
13. [What is the utility of proton pump inhibitor testing in non-cardiac chest pain?].
Huamán JW; Aliaga V; Domenech G; Videla S; Saperas E
Gastroenterol Hepatol; 2014 Oct; 37(8):452-61. PubMed ID: 24725608
[TBL] [Abstract][Full Text] [Related]
14. [Rebamipide using in gastroesophageal reflux disease treatment].
Ivashkin VT; Trukhmanov AS; Gonik MI
Ter Arkh; 2020 May; 92(4):98-104. PubMed ID: 32598706
[TBL] [Abstract][Full Text] [Related]
15. Effect of rebamipide on quality of peptic ulcer healing in rat.
Qi Z; Jie L; Haixia C; Xiaoying Z
Dig Dis Sci; 2009 Sep; 54(9):1876-83. PubMed ID: 19082723
[TBL] [Abstract][Full Text] [Related]
16. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
[TBL] [Abstract][Full Text] [Related]
17. Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials.
Xiong J; Lai S; Zhang P; Li Q; Wei Y; Yang Y; Wang T; Liu L; Ma X; Chen D
Medicine (Baltimore); 2014 Sep; 93(12):e64. PubMed ID: 25211045
[TBL] [Abstract][Full Text] [Related]
18. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
Devault KR
Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):197-205. PubMed ID: 19072410
[TBL] [Abstract][Full Text] [Related]
19. Rebamipide contributes to reducing adverse effects of long-term administration of omeprazole in rats.
Hagiwara T; Mukaisho K; Ling ZQ; Sakano T; Sugihara H; Hattori T
Dig Dis Sci; 2007 Apr; 52(4):988-94. PubMed ID: 17342392
[TBL] [Abstract][Full Text] [Related]
20. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
Azzam RS
Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
